ClinicalTrials.gg
CompletedNCT06493045Updated May 15, 2026Results posted

First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers

A Phase 1 interventional study of IRL757 and Placebo in Not Determined, sponsored by Integrative Research Laboratories AB. Completed at 1 site in Sweden. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Integrative Research Laboratories AB · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, First-In-Human study evaluating the safety and tolerability of single and multiple ascending oral doses of IRL757 in healthy volunteers.

Read the detailed description

The trial is composed of two parts: Single Ascending Dose (SAD) part and Multiple Ascending Dose (MAD) part.

The SAD part of the trial will be a parallel group design with one pre-defined starting dose and up to four tentative ascending dose levels of IRL757. Eligible and consenting participants will be included in one of five cohorts, with 8 participants in each cohort (ratio 1:3 placebo/IRL757).

The MAD part of the trial will start after completion of the SAD part of the trial. Depending on the data from the SAD part, two or three dose levels will be evaluated in the MAD part of the trial. There will be 12 participants in each cohort (ratio 1:3 placebo/IRL757).

At the screening visit, consenting subjects will be screened for eligibility according to study specific inclusion/exclusion criteria within 4 weeks before Investigational Medicinal Product (IMP) administration.

If eligible, participants will be admitted to the phase 1 clinic for allocation and administration of the IMP: single dose in the SAD part of the trial or repeated dose (treatment administered repeatedly for 10 days) in the MAD part of the trial. Participants will receive IRL757 or placebo, as randomized.

The treatment allocation will be double-blind, i.e. it will not be disclosed to the patients, the site staff or the Sponsor.

A follow-up visit will be performed for all participants, 5-10 days after IMP administration.

Safety assessments will be performed throughout the study: review and collection of adverse events, physical examination, suicidality ideation, electrocardiogram recording, vital signs, safety laboratory assessments. Blood and urine sampling will also be performed for determination of pharmacokinetic parameters.

02

Conditions studied

  • Not Determined
03

In context

Lead sponsor

Integrative Research Laboratories AB is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to give written for participation in the trial.
  • Healthy male or female subject aged 18-55 years inclusive.
  • Weight of at least 50 kg and no more than 110 kg at screening.
  • Willing to use highly effective methods of

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the trial, or influence the results or the subject's ability to participate in the trial.
  • History or present clinically significant psychiatric diagnosis, at discretion of the Investigator.
  • Any suicidal ideation of type 4 or 5 in the C-SSRS in the past 3 months (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent).
  • History of seizures, including febrile seizure in childhood.
  • Any clinically significant illness, medical/surgical procedure or trauma within four (4) weeks of the first administration of IMP.
  • Any planned major surgery within the duration of the trial.
  • Any positive result on screening for serum surface antigen, antibody and (HIV).
  • After 10 minutes supine rest at the time of screening, any vital signs values outside the following ranges: Systolic blood pressure > 140 mm Hg, Diastolic blood pressure > 90 mm Hg, Heart rate \< 40 or > 85 beats per minute.
  • Prolonged (> 450 ms for male subjects or > 470 ms for female subjects), cardiac arrhythmias or any clinically significant abnormalities in the resting at the time of screening, as judged by the Investigator.
  • History of severe allergy/ or on-going allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to IRL757.
  • Use of any prescribed or non-prescribed medication including antacids, analgesics, herbal remedies, vitamins and minerals within two (2) weeks prior to the first administration of IMP, except occasional intake of paracetamol (maximum 2 000 mg/day; and not exceeding 3 000 mg/week), at the discretion of the Investigator.
  • Administration of another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical trial that included drug treatment within three (3) months of the first administration of IMP in this trial. Subjects consented and screened but not dosed in previous phase I studies are not excluded.
  • Current smokers or users of nicotine products. Irregular use of nicotine (e.g. smoking, snuffing, chewing tobacco) less than three (3) times per week is allowed before screening visit.
  • History of alcohol abuse or excessive intake of alcohol, as judged by the Investigator.
  • Positive screen for drugs of abuse at screening or on admission to the unit or positive screen for alcohol at screening or on admission to the unit prior to administration of the IMP.
  • Use of anabolic steroids.
  • Current excessive use of caffeine, as judged by the Investigator.
  • Plasma donation within one (1) month of screening or any blood donation/blood loss > 450 mL during the three (3) months prior to screening.
  • Investigator considers the subject unlikely to comply with trial procedures, restrictions and requirements.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    IRL757

    Drug: IRL757

  • Placebo comparator
    Placebo Comparator

    Drug: Placebo

Interventions

  • DrugIRL757

    IRL757 capsule

  • DrugPlacebo

    Placebo capsule

06

What researchers measure

Primary outcomes

  1. Evaluation of Frequency, Seriousness and Intensity of Adverse Events

    Total number of AEs, and total number of AEs by severity and relationship to study treatment are presented. Refer to the Adverse Events section for more information

    Time frame: Until 5-10 days after IMP administration

  2. Description of Physical Examination Findings

    Number of participants with clinically significant abnormal findings on physical examination

    Time frame: Until 5-10 days after IMP administration

  3. Description of Electrocardiogram Findings

    Number of participants with clinically significant abnormal electrocardiogram findings

    Time frame: Until 5-10 days after IMP administration

  4. Description of Vital Signs Findings

    Number of participants with clinically significant abnormal vital signs findings

    Time frame: Until 5-10 days after IMP administration

  5. Description of Safety Laboratory Measurements

    Number of participants with clinically significant abnormal safety laboratory measurements

    Time frame: Until 5-10 days after IMP administration

  6. Description of C-SSRS (Columbia Suicide Severity Rating Scale) Findings

    Number of Participants With Suicidal Thoughts or Attempts

    Time frame: Until 5-10 days after IMP administration

Secondary outcomes

  1. Determination of Maximum Plasma Concentration [Cmax] of IRL757 and Its 3 Main Metabolites

    Geometric mean and geometric coefficient of variation (CV%) for maximum plasma concentration. Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.

    Time frame: Until 48 hours post-dose

  2. Determination of the AUC of IRL757 and Its 3 Main Metabolites After Single and Multiple Dose

    Geometric mean and geometric coefficient of variation (CV%) for area under the plasma concentration-time curve (AUC0-inf for SAD and AUC0-tau for MAD). Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.

    Time frame: Until 48 hours post-dose

  3. Determination of the Time for Maximum Concentration [Tmax] of IRL757 and Its 3 Main Metabolites

    Median time to maximum plasma concentration with full range (minimum, maximum). Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.

    Time frame: Until 48 hours post-dose

  4. Determination of the Half-life [t1/2] of IRL757 and Its 3 Main Metabolites

    Geometric mean and geometric coefficient of variation (CV%) for terminal elimination half-life. Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.

    Time frame: Until 48 hours post-dose

  5. Determination of the Renal Clearance (CLr) of IRL757

    Geometric mean and geometric coefficient of variation (CV%) for renal clearance. Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.

    Time frame: Until 48 hours post-dose

07

Results

Posted May 15, 2026

Participant flow

Participant flow — Overall Study
MilestoneSAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5SAD Placebo CohortSAD Food Interaction Sub-studyMAD Cohort 1MAD Cohort 2MAD Cohort 3MAD Placebo Cohort
Started666661069999
Completed666661069999
Not completed00000000000

Outcome measures

PrimaryEvaluation of Frequency, Seriousness and Intensity of Adverse Events

Total number of AEs, and total number of AEs by severity and relationship to study treatment are presented. Refer to the Adverse Events section for more information

Time frame:
Until 5-10 days after IMP administration
Reported as:
Number · Adverse events
Evaluation of Frequency, Seriousness and Intensity of Adverse Events
Adverse eventsSAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5SAD Placebo CohortSAD Food Interaction Sub-studyMAD Cohort 1MAD Cohort 2MAD Cohort 3MAD Placebo Cohort
Any AE71340991618919
Relationship to study treatment - Not Related312302371145
Relationship to study treatment - Possible401106697514
Relationship to study treatment - Probable00000100000
Severity - Mild71340991518919
Severity - Moderate00000001000
PrimaryDescription of Physical Examination Findings

Number of participants with clinically significant abnormal findings on physical examination

Time frame:
Until 5-10 days after IMP administration
Reported as:
Count of participants · Participants
Description of Physical Examination Findings
ParticipantsSAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5SAD Placebo CohortSAD Food Interaction Sub-studyMAD Cohort 1MAD Cohort 2MAD Cohort 3MAD Placebo Cohort
Description of Physical Examination Findings00000000000
PrimaryDescription of Electrocardiogram Findings

Number of participants with clinically significant abnormal electrocardiogram findings

Time frame:
Until 5-10 days after IMP administration
Reported as:
Count of participants · Participants
Description of Electrocardiogram Findings
ParticipantsSAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5SAD Placebo CohortSAD Food Interaction Sub-studyMAD Cohort 1MAD Cohort 2MAD Cohort 3MAD Placebo Cohort
Description of Electrocardiogram Findings00000000000
PrimaryDescription of Vital Signs Findings

Number of participants with clinically significant abnormal vital signs findings

Time frame:
Until 5-10 days after IMP administration
Reported as:
Count of participants · Participants
Description of Vital Signs Findings
ParticipantsSAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5SAD Placebo CohortSAD Food Interaction Sub-studyMAD Cohort 1MAD Cohort 2MAD Cohort 3MAD Placebo Cohort
Description of Vital Signs Findings00000000000
PrimaryDescription of Safety Laboratory Measurements

Number of participants with clinically significant abnormal safety laboratory measurements

Time frame:
Until 5-10 days after IMP administration
Reported as:
Count of participants · Participants
Description of Safety Laboratory Measurements
ParticipantsSAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5SAD Placebo CohortSAD Food Interaction Sub-studyMAD Cohort 1MAD Cohort 2MAD Cohort 3MAD Placebo Cohort
Description of Safety Laboratory Measurements01000200000
PrimaryDescription of C-SSRS (Columbia Suicide Severity Rating Scale) Findings

Number of Participants With Suicidal Thoughts or Attempts

Time frame:
Until 5-10 days after IMP administration
Reported as:
Count of participants · Participants
Description of C-SSRS (Columbia Suicide Severity Rating Scale) Findings
ParticipantsSAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5SAD Placebo CohortSAD Food Interaction Sub-studyMAD Cohort 1MAD Cohort 2MAD Cohort 3MAD Placebo Cohort
Description of C-SSRS (Columbia Suicide Severity Rating Scale) Findings00000000000
SecondaryDetermination of Maximum Plasma Concentration [Cmax] of IRL757 and Its 3 Main Metabolites

Geometric mean and geometric coefficient of variation (CV%) for maximum plasma concentration. Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.

Time frame:
Until 48 hours post-dose
Reported as:
Geometric mean · umol/L
Determination of Maximum Plasma Concentration [Cmax] of IRL757 and Its 3 Main Metabolites
umol/LSAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5SAD Food Interaction Sub-studyMAD Cohort 1MAD Cohort 2MAD Cohort 3
IRL7572.837 ± 34.55.884 ± 13.29.543 ± 10.724.18 ± 17.711.26 ± 21.99.709 ± 9.872.228 ± 18.76.002 ± 16.512.79 ± 15.7
M10.04644 ± 1380.09647 ± 1320.1563 ± 80.30.3007 ± 65.50.1237 ± 78.50.08305 ± 75.40.03797 ± 1190.03989 ± 72.40.2334 ± 126
M50.09834 ± 12.70.1841 ± 21.80.3745 ± 28.80.6578 ± 20.90.3811 ± 32.80.3352 ± 31.10.1079 ± 19.50.2045 ± 16.80.3451 ± 31.2
M7NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
IRL757 Steady state——————5.059 ± 32.612.24 ± 27.723.27 ± 35.9
M1 Steady state——————0.06238 ± 1030.1093 ± 54.90.4950 ± 76.8
M5 Steady state——————0.1079 ± 17.40.1504 ± 21.80.2328 ± 52.4
M7 Steady state——————NA ± NANA ± NA0.05658 ± 27.6
IRL757 Fed—————7.679 ± 16.2———
M1 Fed—————0.06769 ± 85.2———
M5 Fed—————0.1712 ± 24.6———
M7 Fed—————NA ± NA———
SecondaryDetermination of the AUC of IRL757 and Its 3 Main Metabolites After Single and Multiple Dose

Geometric mean and geometric coefficient of variation (CV%) for area under the plasma concentration-time curve (AUC0-inf for SAD and AUC0-tau for MAD). Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.

Time frame:
Until 48 hours post-dose
Reported as:
Geometric mean · h*umol/L
Determination of the AUC of IRL757 and Its 3 Main Metabolites After Single and Multiple Dose
h*umol/LSAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5SAD Food Interaction Sub-studyMAD Cohort 1MAD Cohort 2MAD Cohort 3
IRL75724.73 ± 58.656.21 ± 40.178.06 ± 37.1403.4 ± 41.2134.0 ± 48.2118.8 ± 18.315.85 ± 18.837.11 ± 20.277.13 ± 22.2
M1NA ± NA1.490 ± 52.11.642 ± 65.55.181 ± 67.61.910 ± 34.61.291 ± 67.00.5716 ± 79.20.3715 ± 67.01.946 ± 111
M51.889 ± 36.53.880 ± 20.35.942 ± 33.014.01 ± 24.17.724 ± 19.37.379 ± 25.90.8983 ± 20.31.734 ± 16.22.879 ± 32.2
M7NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
IRL757 Steady state——————44.66 ± 41.2105.1 ± 36.6184.0 ± 51.8
M1 Steady state——————0.5687 ± 1051.023 ± 53.14.260 ± 72.1
M5 Steady state——————1.209 ± 19.71.674 ± 22.32.479 ± 48.9
M7 Steady state——————NA ± NANA ± NA0.5515 ± 25.6
IRL757 Fed—————144.7 ± 13.9———
M1 Fed—————1.652 ± 76.6———
M5 Fed—————4.792 ± 32.2———
M7 Fed—————NA ± NA———
SecondaryDetermination of the Time for Maximum Concentration [Tmax] of IRL757 and Its 3 Main Metabolites

Median time to maximum plasma concentration with full range (minimum, maximum). Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.

Time frame:
Until 48 hours post-dose
Reported as:
Median · hours
Determination of the Time for Maximum Concentration [Tmax] of IRL757 and Its 3 Main Metabolites
hoursSAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5SAD Food Interaction Sub-studyMAD Cohort 1MAD Cohort 2MAD Cohort 3
IRL7571.517 (0.667 to 2.08)1.508 (0.667 to 3.00)1.000 (0.667 to 1.02)2.000 (1.03 to 6.00)0.8250 (0.667 to 6.00)1.033 (1.00 to 2.00)1.000 (0.667 to 8.00)0.6833 (0.333 to 1.05)0.6833 (0.667 to 2.02)
M13.500 (2.00 to 8.00)4.000 (2.00 to 6.00)3.000 (2.00 to 4.00)4.000 (3.00 to 4.02)3.500 (1.98 to 4.05)3.992 (2.00 to 4.02)3.000 (2.98 to 4.00)3.000 (1.05 to 4.00)3.000 (0.667 to 3.98)
M56.000 (6.00 to 10.0)6.000 (5.98 to 8.00)8.000 (4.00 to 8.03)6.000 (6.00 to 6.10)6.000 (6.00 to 8.00)6.000 (5.92 to 8.00)6.000 (5.93 to 10.1)6.000 (6.00 to 7.98)6.017 (6.00 to 10.0)
M7NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
IRL757 Steady state——————1.017 (0.667 to 3.02)0.9833 (0.667 to 2.02)1.000 (0.667 to 6.03)
M1 Steady state——————3.000 (1.00 to 4.02)2.050 (1.00 to 4.02)3.000 (2.00 to 4.00)
M5 Steady state——————6.000 (2.00 to 6.07)5.983 (1.00 to 6.12)4.000 (0.667 to 6.00)
M7 Steady state——————NA (NA to NA)NA (NA to NA)8.050 (6.00 to 12.0)
IRL757 Fed—————5.983 (3.98 to 8.00)———
M1 Fed—————7.033 (5.98 to 10.0)———
M5 Fed—————11.00 (8.00 to 12.0)———
M7 Fed—————NA (NA to NA)———
SecondaryDetermination of the Half-life [t1/2] of IRL757 and Its 3 Main Metabolites

Geometric mean and geometric coefficient of variation (CV%) for terminal elimination half-life. Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.

Time frame:
Until 48 hours post-dose
Reported as:
Geometric mean · hours
Determination of the Half-life [t1/2] of IRL757 and Its 3 Main Metabolites
hoursSAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5SAD Food Interaction Sub-studyMAD Cohort 1MAD Cohort 2MAD Cohort 3
IRL7576.681 ± 40.06.813 ± 36.75.874 ± 33.511.35 ± 22.38.969 ± 48.19.659 ± 8.926.174 ± 27.56.193 ± 23.65.925 ± 33.0
M1NA ± NA5.202 ± 27.05.495 ± 47.110.28 ± 32.39.538 ± 45.29.514 ± 22.37.645 ± 17.67.111 ± 36.16.185 ± 66.9
M510.30 ± 31.911.69 ± 28.38.791 ± 21.613.08 ± 14.411.47 ± 29.013.05 ± 15.215.15 ± 78.612.35 ± 51.110.87 ± 32.0
M7NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
IRL757 Steady state——————12.05 ± 19.811.65 ± 29.910.50 ± 38.2
M1 Steady state——————10.59 ± 39.813.03 ± 61.211.07 ± 43.3
M5 Steady state——————23.95 ± 34.223.48 ± 30.320.36 ± 44.6
M7 Steady state——————NA ± NANA ± NA82.96 ± 39.2
IRL757 Fed—————10.47 ± 9.68———
M1 Fed—————11.84 ± 30.2———
M5 Fed—————15.20 ± 2.06———
M7 Fed—————NA ± NA———
SecondaryDetermination of the Renal Clearance (CLr) of IRL757

Geometric mean and geometric coefficient of variation (CV%) for renal clearance. Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.

Time frame:
Until 48 hours post-dose
Reported as:
Geometric mean · L/h
Determination of the Renal Clearance (CLr) of IRL757
L/hSAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5MAD Cohort 1MAD Cohort 2MAD Cohort 3
IRL757 Day 10.09142 ± 83.80.06989 ± 38.60.1260 ± 26.70.09058 ± 64.50.08338 ± 33.1———
IRL757 Steady state—————0.1141 ± 46.40.08829 ± 47.00.08091 ± 42.2

Adverse events

Collected over From first IMP administration until follow-up visit 5-10 days after last IMP administration. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SAD Cohort 10/6 (0%)0/6 (0%)4/6 (66.7%)
SAD Cohort 20/6 (0%)0/6 (0%)1/6 (16.7%)
SAD Cohort 30/6 (0%)0/6 (0%)2/6 (33.3%)
SAD Cohort 40/6 (0%)0/6 (0%)3/6 (50%)
SAD Cohort 50/6 (0%)0/6 (0%)0/6 (0%)
SAD Placebo Cohort0/10 (0%)0/10 (0%)6/10 (60%)
SAD Food Interaction Sub-study0/6 (0%)0/6 (0%)4/6 (66.7%)
MAD Cohort 10/9 (0%)0/9 (0%)7/9 (77.8%)
MAD Cohort 20/9 (0%)0/9 (0%)8/9 (88.9%)
MAD Cohort 30/9 (0%)0/9 (0%)4/9 (44.4%)
MAD Placebo Cohort0/9 (0%)0/9 (0%)8/9 (88.9%)
Most frequent other events
Showing 10 of 37
Most frequent other events
EventSAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5SAD Placebo CohortSAD Food Interaction Sub-studyMAD Cohort 1MAD Cohort 2MAD Cohort 3MAD Placebo Cohort
HeadacheNervous system disorders2/60/60/60/60/63/101/63/94/92/94/9
FatigueGeneral disorders2/60/61/60/60/61/100/60/91/90/90/9
NasopharyngitisInfections and infestations0/60/61/61/60/60/101/60/92/91/93/9
DizzinessNervous system disorders0/60/60/60/60/62/102/60/91/90/90/9
NauseaGastrointestinal disorders0/60/60/61/60/60/100/60/90/90/92/9
Dermatitis contactSkin and subcutaneous tissue disorders0/60/60/60/60/60/100/62/90/90/90/9
HyperprolactinaemiaEndocrine disorders0/60/60/60/60/62/100/60/90/90/90/9
DiarrhoeaGastrointestinal disorders0/60/60/60/60/60/101/61/90/90/90/9
FlatulenceGastrointestinal disorders0/60/60/60/60/60/101/60/90/90/91/9
Medical device site reactionInjury, poisoning and procedural complications1/60/60/60/60/60/100/60/90/90/90/9

Baseline characteristics

Age, Continuous
Age, Continuous(Years)SAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5SAD Placebo CohortSAD Food Interaction Sub-studyMAD Cohort 1MAD Cohort 2MAD Cohort 3MAD Placebo CohortTotal
Mean35.0 ± 12.534.2 ± 6.028.2 ± 7.040.5 ± 13.436.2 ± 8.933.3 ± 8.638.8 ± 12.334.6 ± 7.738.1 ± 9.937.1 ± 12.532.2 ± 11.135.2 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)SAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5SAD Placebo CohortSAD Food Interaction Sub-studyMAD Cohort 1MAD Cohort 2MAD Cohort 3MAD Placebo CohortTotal
Female2334273233436
Male4332433766546
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5SAD Placebo CohortSAD Food Interaction Sub-studyMAD Cohort 1MAD Cohort 2MAD Cohort 3MAD Placebo CohortTotal
Hispanic or Latino001000110003
Not Hispanic or Latino66566105899979
Unknown or Not Reported000000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SAD Cohort 1SAD Cohort 2SAD Cohort 3SAD Cohort 4SAD Cohort 5SAD Placebo CohortSAD Food Interaction Sub-studyMAD Cohort 1MAD Cohort 2MAD Cohort 3MAD Placebo CohortTotal
American Indian or Alaska Native000000000000
Asian100000011104
Native Hawaiian or Other Pacific Islander000000000000
Black or African American000010000001
White56565105888975
More than one race001000100002
Unknown or Not Reported000000000000
08

Study locations

1 site
  • CTC Clinical Trial Consultants AB, Uppsala University Hospital
    Uppsala, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Feb 2025, 8 months.

Results were first posted in May 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jul 9, 2024
StartActual
May 16, 2024
Primary completionActual
Feb 7, 2025
CompletionActual
Feb 7, 2025
Results first posted
May 15, 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06493045
Lead sponsor
Integrative Research Laboratories AB
Collaborators
Michael J. Fox Foundation for Parkinson's Research
Responsible party
Sponsor
First posted
Jul 9, 2024
Start date
May 16, 2024
Primary completion
Feb 7, 2025
Completion
Feb 7, 2025
Results posted
May 15, 2026
Last update
May 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IRL757

Start the discussion